PHASE-II TRIAL OF CISPLATIN IN SMALL CELL-CARCINOMA OF THE LUNG

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (9-10) , 905-907
Abstract
Eighteen patients with histologically documented small cell carcinoma of the lung who had failed initial combination chemotherapy regimens were treated with single-agent cisplatin in a dose of 100 mg/m2 every 3 wk, with mannitol and fluid diuresis. Tumor regression was limited to 1 partial response (response rate, 6%; 95% confidence limits, 1%-27%). Significant toxic effects were gastrointestinal (severe nausea and vomiting in 12 of 14 patients) and hematologic (severe leukopenia in 1 patient and severe thrombocytopenia in 3). The antitumor efficacy of high-dose cisplatin in heavily pretreated patients with small cell carcinoma of the lung appears to be marginal.

This publication has 1 reference indexed in Scilit: